Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables.
BACKGROUND
Lung cancer is one of the most common causes of cancer deaths worldwide. Adenocarcinoma is taking over squamous cell lung cancer as the predominant histological subtype. Several cytotoxic drugs are available for the treatment of lung cancer, but side effects limit their use. Recently, targeted therapies for cancers have come into clinical practice.


OBJECTIVE
To determine the prevalence of epidermal growth factor receptor (EGFR) mutation in adenocarcinoma lung in a North Indian population and its relation with different clinical variables.


METHODS
A total of 57 patients who met inclusion criteria were recruited into the study. Relevant history, clinical examination and investigations were done. EGFR mutation was done in all patients.


RESULTS
A total of twenty patients tested positive for EGFR mutation. EGFR was more frequently detected in female patients (53.8%), while as only 19.4% of the male patients expressed EGFR mutation, which was statistically very significant (P = 0.007). EGFR mutation was more frequently detected in nonsmokers (52%) as compared to smokers (21.9%) which also was statistically significant (P value of 0.018). EGFR mutation was more common in Stage III and IV adenocarcinomas (48%) as compared to Stage I and II (21.4%) which was statistically significant (P value 0.034).


CONCLUSIONS
EGFR mutation should be routinely done in all patients of adenocarcinoma lung particularly non-smoker females with Stage III and IV disease.
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Basharat Ahmad
BA
Kasana
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Waseem Raja
WR
Dar
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Sheikh Aijaz
SA
Aziz
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Abdul Rashid
AR
Lone
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Najeeb Ullah
NU
Sofi
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Imtiyaz Ahmad
IA
Dar
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Muzamil
M
Latief
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Faheem
F
Arshad
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Moomin
M
Hussain
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India.
Mir
M
Hussain
Adenocarcinoma lung; epidermal growth factor receptor; geftinib
N Engl J Med. 2009 Sep 3;361(10):958-67
19692684
Lung India. 2014 Jan;31(1):23-8
24669077
Nature. 2009 Apr 9;458(7239):719-24
19360079
J Clin Oncol. 2005 Feb 1;23(4):857-65
15681531
Korean J Intern Med. 2009 Mar;24(1):48-54
19270482
Clin Cancer Res. 2005 Feb 1;11(3):1167-73
15709185
Indian J Cancer. 2013 Apr-Jun;50(2):102-6
23979199
Br Med Bull. 2003;68:71-94
14757710
J Clin Oncol. 2001 Mar 15;19(6):1734-42
11251004
J Clin Oncol. 2004 Jan 15;22(2):330-53
14691125
N Engl J Med. 2008 Sep 25;359(13):1367-80
18815398
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22
16203769
Br J Cancer. 2008 Dec 2;99(11):1757-62
18985035
Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9
12422308
J Clin Oncol. 2008 May 20;26(15):2442-9
18458038
Mod Pathol. 2010 Feb;23 (2):159-68
19855375
Cell Res. 2005 Mar;15(3):212-7
15780185
Science. 2004 Jun 4;304(5676):1497-500
15118125
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
15329413
Lung Cancer. 2011 Sep;73(3):316-9
21315473
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Asian Pac J Cancer Prev. 2013;14(6):3705-9
23886169
Indian J Chest Dis Allied Sci. 2006 Jul-Sep;48(3):187-90
18610676
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
15741570
Respirology. 2003 Dec;8(4):513-21
14629658
Semin Oncol. 2002 Oct;29(5 Suppl 14):38-44
12422312
Cancer Res. 2004 Dec 15;64(24):8919-23
15604253
BMJ Open. 2013 Apr 03;3(4):null
23558737
Am J Epidemiol. 2003 Oct 1;158(7):609-16; discussion 617-20
14507595
J Clin Oncol. 2005 Apr 10;23(11):2513-20
15738541
BMJ. 1995 Oct 7;311(7010):899-909
7580546
Ann Oncol. 2012 Jul;23 (7):1738-43
22100693
Br J Cancer. 2005 Aug 8;93(3):355-63
16052218
Nature. 2007 Aug 2;448(7153):561-6
17625570
Lancet Oncol. 2011 Feb;12(2):175-80
21277552